View More
Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Dr Yara Abdou discusses BRCA mutation testing and adjuvant therapy with olaparib in BRCA-mutated, HER2-negative early breast cancer, from Clinical Care Options (CCO)
Yara Abdou, MD
Physicians:
maximum of 0.75 AMA PRA Category 1 Credits™
Registered Nurses:
0.75 Nursing contact hours
Pharmacists:
0.75 contact hours (0.075 CEUs)
Released: May 17, 2022
Expired:
May 16, 2023
Slideset from Dr Yara Abdou on adjuvant olaparib in BRCA1/2-mutated, HER2-negative early breast cancer, from Clinical Care Options (CCO)
Yara Abdou, MD
Released: May 17, 2022
Dr. Yara Abdou discusses Ki-67 testing and adjuvant abemaciclib in HR+/HER2-, node-positive, high-risk early breast cancer, from Clinical Care Options (CCO)
Yara Abdou, MD
Physicians:
maximum of 0.5 AMA PRA Category 1 Credits™
Registered Nurses:
0.5 Nursing contact hours
Pharmacists:
0.5 contact hours (0.05 CEUs)
Released: May 12, 2022
Expired:
May 11, 2023
Slideset from Dr. Yara Abdou on Ki-67 and adjuvant abemaciclib for HR+/HER2-, node-positive, high-risk EBC, from Clinical Care Options (CCO)
Yara Abdou, MD
Released: May 12, 2022
For further information concerning Lilly grant funding,
visit www.lillygrantoffice.com.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.